Asymptomatic Ventricular Dysfunction and HFrEF Secondary to Classic Chemotherapy

Introduction Advances in oncology, such as better access to the health care system, earlier cancer diagnosis, and new chemotherapies, have led longer survival of patients with over last decades. However, this population is vulnerable drug-related adverse cardiovascular events, like cardiomyopathy, which leads heart failure impairs quality life., Among different classes chemotherapeutic agents, classically anthracyclines trastuzumab stand out most related cardiomyopathy. Anthracyclines may cause cardiac dysfunction [...]